Discovering how oncogenes remodel the surfaceome of cells

发现癌基因如何重塑细胞表面组

• 批准号: 10212408
• 负责人: JAMES A WELLS
• 金额: $ 53.49万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10212408
• 关键词: Amines; Antibodies; Antineoplastic Agents; BRAF gene; Bacteriophages; Bar Codes; Biological Markers; Cell Line; Cell Surface Proteins; Cell surface; Cells; Collaborations; DNA; Data Set; Drug Targeting; Epidermal Growth Factor Receptor; Event; Foundations; Goals; Human; KRAS2 gene; Lead; Logic; MEKs; Malignant Neoplasms; Mass Spectrum Analysis; Measures; Membrane; Membrane Proteins; Methods; Molecular; Mutation; N-terminal; Oncogenes; Oncogenic; Patients; Phage Display; Polysaccharides; Population; Proteins; Proteome; Proteomics; Recombinant Antibody; Regulation; Sampling; Signal Transduction; Surface; Technology; Tissues; antibody detection; base; cancer cell; metaplastic cell transformation; new technology; new therapeutic target; next generation sequencing; particle

Title: Discovering how oncogenes remodel the surfaceome of cells Abstract: The cell surface is the primary hub for cells to communicate with the outside world. Cancer cells have numerous challenges for survival and we hypothesize many of these start at the cell surface made up of some 3000-4000 proteins. Our primary goal is to systematically understand how cancer cells remodel their membrane proteomes (surfaceomes) during oncogenic transformation to survive. We propose to develop enabling technologies for surfaceomics at the population, single cell, and tissue level. We will generate foundational data sets to understand the molecular logic and signaling mechanisms behind the coordinated remodeling events that drive cellular transformation. (Fig 1). We will focus our studies on mutationally activated KRAS and five other highly proliferative oncogenes (EGFR, BRAF, MEK, Akt and PI3K) that together are found in nearly half of all human cancers. We will study how these oncogenes induce coordinate changes in the surfaceome compared to isogenic cells of the same type, in patient derived cancer cells and tissues. We propose new mass spectrometry-based methods to allow for quantification of membrane proteins using two complementary enrichment methods that target surface glycans or surface N-terminal α-amines. We will also develop a new, highly sensitive and multiplexed technology (phage-antibody next generation sequencing, or PhaNGS) to simultaneously detect 100s of surface proteins in very small Figure 1. (A) To understand how oncogenes such as KRAS induce massive cellular changes we will (B) develop new technologies to measure surfaceome changes to understand coordinate regulation, and identify new drug targets. samples or even single cells. The Antibiome Center, which I direct, in collaboration with the Recombinant Antibody Network, has produced recombinant antibodies to 100s of cell surface proteins using Fab-phage display. Each Fab-phage is essentially a DNA barcoded antibody because it has a functional Fab displayed from the phage particle with the DNA encoding it inside. PhaNGS has tremendous potential for highly multiplexed, inexpensive and ultrasensitive means of probing 1000s of cells or cell lines for changes in their surfaceomes. I am excited that these studies will reveal how coordinate remodeling of membrane protein teams contributes to cell state changes. I believe we will also discover new biomarkers and cancer drug targets.

题目：发现癌基因如何重塑细胞表面